Protocolized warfarin reversal with 4-factor prothrombin complex concentrate versus 3-factor prothrombin complex concentrate with recombinant factor VIIa

Cassie A. Barton, Marissa Hom, Nathan B. Johnson, Jon Case, Ran Ran, Martin Schreiber

    Research output: Contribution to journalArticle

    3 Citations (Scopus)

    Abstract

    Introduction: Life-threatening bleeding can complicate warfarin therapy. Rapid anticoagulant reversal via replacement of vitamin-K dependent clotting factors is essential for hemostasis. We compare two methods of rapid factor replacement for warfarin reversal. Methods: A retrospective cohort study of warfarin-treated patients experiencing life-threatening bleeding who received a reversal protocol comprised of 4F PCC or 3F PCC and rFVIIa was performed. Demographic, clinical and anticoagulant reversal information, and all adverse events attributed to warfarin reversal were recorded. Results: 195 patients were included in final analysis. While baseline demographics were similar between groups, the 3F-PCC group had a longer ICU LOS and higher in-hospital mortality (p < .01, .01).Pre-reversal INR was similar between both groups, but post-reversal INR was significantly lower in the 3F-PCC group, 0.8 versus 1.3 (p < .01). Significantly more patients experienced thromboembolic complications in the 3F-PCC group than the 4F-PCC group (p < .01). Receipt of rFVIIa was significantly associated with thromboembolic complications. Discussion: A 4F PCC reversal strategy is efficacious in INR reversal and provides lower thromboembolic risk as compared to 3F PCC with rFVIIa.

    Original languageEnglish (US)
    JournalAmerican Journal of Surgery
    DOIs
    StateAccepted/In press - Jan 1 2018

    Fingerprint

    Warfarin
    International Normalized Ratio
    Anticoagulants
    Demography
    Hemorrhage
    Blood Coagulation Factors
    Vitamin K
    Hospital Mortality
    Hemostasis
    Cohort Studies
    Retrospective Studies
    prothrombin complex concentrates
    recombinant FVIIa
    Therapeutics

    Keywords

    • Anticoagulation
    • Prothrombin complex concentrate
    • Recombinant factor VIIa
    • Reversal
    • Warfarin

    ASJC Scopus subject areas

    • Surgery

    Cite this

    Protocolized warfarin reversal with 4-factor prothrombin complex concentrate versus 3-factor prothrombin complex concentrate with recombinant factor VIIa. / Barton, Cassie A.; Hom, Marissa; Johnson, Nathan B.; Case, Jon; Ran, Ran; Schreiber, Martin.

    In: American Journal of Surgery, 01.01.2018.

    Research output: Contribution to journalArticle

    @article{842ba5ae6530485a968a14005d3e8380,
    title = "Protocolized warfarin reversal with 4-factor prothrombin complex concentrate versus 3-factor prothrombin complex concentrate with recombinant factor VIIa",
    abstract = "Introduction: Life-threatening bleeding can complicate warfarin therapy. Rapid anticoagulant reversal via replacement of vitamin-K dependent clotting factors is essential for hemostasis. We compare two methods of rapid factor replacement for warfarin reversal. Methods: A retrospective cohort study of warfarin-treated patients experiencing life-threatening bleeding who received a reversal protocol comprised of 4F PCC or 3F PCC and rFVIIa was performed. Demographic, clinical and anticoagulant reversal information, and all adverse events attributed to warfarin reversal were recorded. Results: 195 patients were included in final analysis. While baseline demographics were similar between groups, the 3F-PCC group had a longer ICU LOS and higher in-hospital mortality (p < .01, .01).Pre-reversal INR was similar between both groups, but post-reversal INR was significantly lower in the 3F-PCC group, 0.8 versus 1.3 (p < .01). Significantly more patients experienced thromboembolic complications in the 3F-PCC group than the 4F-PCC group (p < .01). Receipt of rFVIIa was significantly associated with thromboembolic complications. Discussion: A 4F PCC reversal strategy is efficacious in INR reversal and provides lower thromboembolic risk as compared to 3F PCC with rFVIIa.",
    keywords = "Anticoagulation, Prothrombin complex concentrate, Recombinant factor VIIa, Reversal, Warfarin",
    author = "Barton, {Cassie A.} and Marissa Hom and Johnson, {Nathan B.} and Jon Case and Ran Ran and Martin Schreiber",
    year = "2018",
    month = "1",
    day = "1",
    doi = "10.1016/j.amjsurg.2017.12.011",
    language = "English (US)",
    journal = "American Journal of Surgery",
    issn = "0002-9610",
    publisher = "Elsevier Inc.",

    }

    TY - JOUR

    T1 - Protocolized warfarin reversal with 4-factor prothrombin complex concentrate versus 3-factor prothrombin complex concentrate with recombinant factor VIIa

    AU - Barton, Cassie A.

    AU - Hom, Marissa

    AU - Johnson, Nathan B.

    AU - Case, Jon

    AU - Ran, Ran

    AU - Schreiber, Martin

    PY - 2018/1/1

    Y1 - 2018/1/1

    N2 - Introduction: Life-threatening bleeding can complicate warfarin therapy. Rapid anticoagulant reversal via replacement of vitamin-K dependent clotting factors is essential for hemostasis. We compare two methods of rapid factor replacement for warfarin reversal. Methods: A retrospective cohort study of warfarin-treated patients experiencing life-threatening bleeding who received a reversal protocol comprised of 4F PCC or 3F PCC and rFVIIa was performed. Demographic, clinical and anticoagulant reversal information, and all adverse events attributed to warfarin reversal were recorded. Results: 195 patients were included in final analysis. While baseline demographics were similar between groups, the 3F-PCC group had a longer ICU LOS and higher in-hospital mortality (p < .01, .01).Pre-reversal INR was similar between both groups, but post-reversal INR was significantly lower in the 3F-PCC group, 0.8 versus 1.3 (p < .01). Significantly more patients experienced thromboembolic complications in the 3F-PCC group than the 4F-PCC group (p < .01). Receipt of rFVIIa was significantly associated with thromboembolic complications. Discussion: A 4F PCC reversal strategy is efficacious in INR reversal and provides lower thromboembolic risk as compared to 3F PCC with rFVIIa.

    AB - Introduction: Life-threatening bleeding can complicate warfarin therapy. Rapid anticoagulant reversal via replacement of vitamin-K dependent clotting factors is essential for hemostasis. We compare two methods of rapid factor replacement for warfarin reversal. Methods: A retrospective cohort study of warfarin-treated patients experiencing life-threatening bleeding who received a reversal protocol comprised of 4F PCC or 3F PCC and rFVIIa was performed. Demographic, clinical and anticoagulant reversal information, and all adverse events attributed to warfarin reversal were recorded. Results: 195 patients were included in final analysis. While baseline demographics were similar between groups, the 3F-PCC group had a longer ICU LOS and higher in-hospital mortality (p < .01, .01).Pre-reversal INR was similar between both groups, but post-reversal INR was significantly lower in the 3F-PCC group, 0.8 versus 1.3 (p < .01). Significantly more patients experienced thromboembolic complications in the 3F-PCC group than the 4F-PCC group (p < .01). Receipt of rFVIIa was significantly associated with thromboembolic complications. Discussion: A 4F PCC reversal strategy is efficacious in INR reversal and provides lower thromboembolic risk as compared to 3F PCC with rFVIIa.

    KW - Anticoagulation

    KW - Prothrombin complex concentrate

    KW - Recombinant factor VIIa

    KW - Reversal

    KW - Warfarin

    UR - http://www.scopus.com/inward/record.url?scp=85040457323&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85040457323&partnerID=8YFLogxK

    U2 - 10.1016/j.amjsurg.2017.12.011

    DO - 10.1016/j.amjsurg.2017.12.011

    M3 - Article

    C2 - 29338845

    AN - SCOPUS:85040457323

    JO - American Journal of Surgery

    JF - American Journal of Surgery

    SN - 0002-9610

    ER -